Multivariate analysis adjusted by gender, age, tumor size, recurrence, and IDH1 mutant status indicated the hazard ratio for VAP-1 co-expressed with CD68 or CD163 enhanced the prognostic capability significantly in gliomas (VAP-1/CD68, HR: 3.226, 95% CI: 1.980–5.256, p < 0.0001; VAP-1/CD163, HR: 6.597, 95% CI: 3.677–11.836, p < 0.0001; Table 4). Here, CD163 is linked to neoplasm.